Scienture Expands REZENOPY Nasal Spray Distribution to U.S. Addiction Treatment Centers

Scienture Holdings Inc. (SCNX) said Sept. 22, 2026, that its subsidiary, Scienture, LLC, signed an agreement with a distribution partner to broaden U.S. commercial access to REZENOPY Nasal Spray 10 mg, targeting addiction treatment centers. The deal extends the product's reach beyond its existing commercial channels into the addiction treatment segment. Financial terms of the agreement were not disclosed. Scienture Holdings traded under the ticker SCNX. The company did not provide revenue guidance or a timeline for the expanded distribution rollout.